Catalent (Catalent) Float Percentage Of Total Shares Outstanding : 78.27% (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Catalent Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Catalent's float shares is 141.65 Mil. Catalent's total shares outstanding is 180.97 Mil. Catalent's float percentage of total shares outstanding is 78.27%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Catalent's Insider Ownership is 1.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Catalent's Institutional Ownership is 79.13%.

Catalent Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Catalent's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	141.65	/	180.97
	=	78.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalent (Catalent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

0C8:Germany 0C8:Germany

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Executives

David Mcerlane	officer: Group President, Biologics	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg	director	ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan	director	214 PARK BLVD S, VENICE FL 34285
John J Greisch	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey	director	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio	director	C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood	officer: Pres. Pharma Prod Delivery Div	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt	officer: Pres. Consumer Health Div	C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson	officer: VP, Chief Accounting Officer	CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti	officer: SVP Global Ops Small Molecule	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda	officer: SVP, Human Resources	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli	officer: See remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold	officer: SVP, CIO	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873